prismmarketview
Nov 19, 7:13 PM
$CING: U.S. Patent No. 12,797,335 (trimodal, precision-timed release buspirone tablet) for CTx-2103 (anxiety, investigational)
→ Formulation patent, not a patent on buspirone
→ Priority is still resubmitting the CTx-1301 (ADHD) application; 2H 2027 target if approved
Caveats: IP only. CTx-2103 development starts after CTx-1301 approval, with no timeline.
$CING #Biotech
https://prismmarketview.com/cingulate-secures-u-s-patent-for-anxiety-drug-formulation-keeps-focus-on-adhd-candidate/
0 replies